Amounts too small to produce a psychedelic experience, on a fixed schedule for weeks. Users report better mood, energy, and focus, and scores improve — but against matched placebo most of the difference disappears. Long-term heart-valve safety has never been measured. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting blood pressure | 105–120 / 65–78 mmHg | The most consistent objective adverse effect |
| Echocardiogram (valve morphology and regurgitation grade) | Trace regurgitation or less | 5-HT2B fibrosis is silent until advanced |
| Resting heart rate | 50–65 bpm | Tracks sympathetic load from dosing |
| hs-CRP | Below 0.5 mg/L | Tests the anti-inflammatory mechanism claim |
| ALT and AST | Both 10–26 U/L | Clearance depends on hepatic glucuronidation |
| eGFR | Above 90 mL/min/1.73 m² | Metabolites are renally excreted |
| PHQ-9 and GAD-7 | Both below 5 | The primary claimed benefit |
| Sustained attention or cognitive-control task | Stable or improved | The one replicated pharmacological effect |
| Fasting insulin and HbA1c | Below 5 µIU/mL; 4.8–5.2% | The metabolic backdrop for longevity claims |
Cadence: Blood pressure baseline and weekly in active blocks; psychological measures baseline, weeks 2 and 4, block end; blood panel baseline and every 6–12 months; echocardiography baseline and 12 months.